natgillin/translations-raw huggingface dataset:
The most important side effects with Lemtrada are autoimmune conditions (where the body's defence system attacks normal tissue), including thyroid gland disorders, immune thrombocytopenic purpura (a bleeding disorder caused by low blood platelet counts) and kidney damage, as well as low blood cell counts, reactions to the infusion and infections. 
Najpomembnejši neželeni učinki zdravila Lemtrada so avtoimunska stanja (pri katerih obrambni mehanizem telesa napade normalno tkivo), vključno z boleznimi ščitnice, imunsko trombocitopenično purpuro (motnjo strjevanja krvi, ki jo povzroča nizko število rdečih krvnih celic), okvaro ledvic, nizkim številom krvnih celic, z infuzijo povezanimi reakcijami in okužbami.
Patients should receive certain medicines before or during treatment to reduce the side effects. 
Za zmanjšanje neželenih učinkov morajo bolniki pred zdravljenjem ali med njim prejemati določena zdravila.
How is Lemtrada used? 
Kako se zdravilo Lemtrada uporablja?
In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and optic nerve [nerve that sends signals from the eye to the brain]), causing inflammation that damages the nerves and the insulation around them. 
Pri multipli sklerozi se imunski sistem (naravni obrambni mehanizem telesa) ne odziva normalno in napada dele osrednjega živčevja (možgane, hrbtenjačo in optični živec [živec, ki pošilja signale iz očesa v možgane]) ter povzroča vnetje, ki poškoduje živce in zaščitno ovojnico okrog njih.
Lemtrada can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Lemtrada je le na recept.
Up to two additional courses, each of 12 mg daily for 3 days, can be given at 12-month intervals. 
V 12-mesečnih razmikih je mogoče zdravilo dati v še največ dveh dodatnih tridnevnih ciklih z odmerkom 12 mg dnevno.
For the full list of side effects of Lemtrada, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Lemtrada, glejte navodilo za uporabo.
The medicine must not be used in patients with autoimmune diseases besides MS. For the full list of restrictions, see the package leaflet. 
Prav tako se ne sme uporabljati pri bolnikih z drugimi avtoimunskimi boleznimi poleg multiple skleroze.
How does Lemtrada work? 
Kako zdravilo Lemtrada deluje?
Lemtrada contains the active substance alemtuzumab. 
Zdravilo Lemtrada vsebuje učinkovino alemtuzumab.
It is available as tablets (100 mg). 
Na voljo je v obliki tablet (100 mg).
The full EPAR for Lamivudine Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lamivudine Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Lamivudine Teva on 23 October 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Lamivudine Teva, veljavno po vsej Evropski uniji, odobrila dne 23. oktobra 2009.
This means that Lamivudine Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zeffix. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Zeffix.
EPAR summary for the public lamivudine 
Povzetek EPAR za javnost lamivudin
What are the benefits and risks of Lamivudine Teva? 
Kakšne so koristi in tveganja, povezani z zdravilom Lamivudine Teva?
It is used in patients with compensated liver disease (when the liver is damaged but functions normally), who also show signs that the virus is still multiplying, and have signs of liver damage (raised levels of the liver enzyme ‘alanine aminotransferase' [ALT] and signs of damage when liver tissue is examined under a microscope). 
Uporablja se pri bolnikih s kompenzirano boleznijo jeter (jetra so poškodovana, a delujejo normalno), ki kažejo tudi znake še vedno potekajočega razmnoževanja virusa in znake okvare jeter (povišane ravni jetrnega encima „alanin-aminotransferaze“ [ALT] in znake poškodb, ki so vidni pod mikroskopom).
For more information about treatment with Lamivudine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Lamivudine Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
If the hepatitis B virus can still be found in the blood after six months of treatment, the doctor should consider changing treatment to reduce the risk of resistance. 
Če je po šestih mesecih zdravljenja virus hepatitisa B v krvi še vedno prisoten, mora zdravnik razmisliti o spremembi zdravljenja, da se zmanjša tveganje za razvoj odpornosti.
This is a summary of the European public assessment report (EPAR) for Lamivudine Teva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lamivudine Teva.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine Teva. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Lamivudine Teva, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Because Lamivudine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine. 
Ker je zdravilo Lamivudine Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Lamivudine Teva is a ‘generic medicine'. 
Lamivudine Teva je „generično zdravilo“.
Lamivudine Teva is used to treat adult patients who have chronic (long term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus). 
Zdravilo Lamivudine Teva se uporablja za zdravljenje odraslih bolnikov s kroničnim (dolgotrajnim) hepatitisom B (okvaro jeter zaradi okužbe z virusom hepatitisa B).
Patients infected with a virus that has the ‘YMDD mutation' (a change in the virus's DNA that is often found after treatment with lamivudine) should take Lamivudine Teva in combination with another medicine against hepatitis B. For more information, please see the Summary of Product Characteristics (also part of the EPAR). 
Bolniki, okuženi z YMDD mutacijo virusa (tj. spremembo v virusni DNK, ki je pogosta po zdravljenju z lamivudinom), morajo zdravilo Lamivudine Teva jemati v kombinaciji z drugim zdravilom proti hepatitisu B. Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Treatment with Lamivudine Teva should be initiated by a doctor who has experience in the management of chronic hepatitis B. The recommended dose of Lamivudine Teva is 100 mg once a day. 
Zdravljenje z zdravilom Lamivudine Teva mora uvesti zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa B. Priporočeni odmerek zdravila Lamivudine Teva je 100 mg enkrat na dan.
Because the hepatitis B virus can become resistant to Lamivudine Teva, the doctor should only consider prescribing Lamivudine Teva if other treatments that are less likely to lead to resistance cannot be used. 
Ker lahko virus hepatitisa B postane odporen na zdravilo Lamivudine Teva, naj ga zdravnik predpiše le, če drugih zdravil, pri katerih obstaja manjša verjetnost, da bo prišlo do razvoja odpornosti, ni mogoče uporabiti.
Therefore, the CHMP's view was that, as for Zeffix, the benefit outweighs the identified risk. 
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Zeffix, odtehtajo znana tveganja.
The Committee recommended that Lamivudine Teva be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Lamivudine Teva odobri dovoljenje za promet.
Lamivudine interferes with the action of a viral enzyme, DNA polymerase, which is involved in the formation of viral DNA. 
Lamivudin zavira delovanje virusnega encima DNK-polimeraze, ki je udeležen pri tvorbi virusne DNK.
Other information about Lamivudine Teva 
Druge informacije o zdravilu Lamivudine Teva:
Because Lamivudine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Zeffix. 
Ker je zdravilo Lamivudine Teva generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Zeffix.
Lamivudine Teva is a medicine that contains the active substance lamivudine. 
Lamivudine Teva je zdravilo, ki vsebuje zdravilno učinkovino lamivudin.
The CHMP concluded that, in accordance with EU requirements, Lamivudine Teva has been shown to have comparable quality and to be bioequivalent to Zeffix. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Lamivudine Teva primerljivo raven kakovosti kot zdravilo Zeffix ter da mu je biološko enakovredno.
The active substance in Lamivudine Teva, lamivudine, is an antiviral agent belonging to the class of the nucleoside analogues. 
Zdravilna učinkovina zdravila Lamivudine Teva, lamivudin, je protivirusna učinkovina, ki spada v razred nukleozidnih analogov.
Why has Lamivudine Teva been approved? 
Zakaj je bilo zdravilo Lamivudine Teva odobreno?
Lamivudine Teva is not suitable for patients who require doses below 100 mg. 
Zdravilo Lamivudine Teva ni primeren za bolnike, ki potrebujejo odmerke, nižje od 100 mg. Trajanje zdravljenja je odvisno od bolnikovega stanja in odziva na zdravljenje.
How has Lamivudine Teva been studied? 
Kako je bilo zdravilo Lamivudine Teva raziskano?
What is Lamivudine Teva? 
Kaj je zdravilo Lamivudine Teva?
The dose needs to be lowered for patients who have problems with their kidneys. 
Pri bolnikih, ki imajo težave z ledvicami, bo odmerek morda treba prilagoditi.
How is Lamivudine Teva used? 
Kako se zdravilo Lamivudine Teva uporablja?
What is Lamivudine Teva used for? 
Za kaj se zdravilo Lamivudine Teva uporablja?
How does Lamivudine Teva work? 
Kako zdravilo Lamivudine Teva deluje?
It should be given twice a week for 12 weeks, and then once a week for 24 weeks. 
Daje se dvakrat tedensko v obdobju 12 tednov, zatem pa enkrat tedensko še 24 tednov.
The patients were followed up for up to 10 years. 
Stanje bolnikov so spremljali do 10 let.
The main measure of effectiveness was the number of patients who survived without the disease coming back. 
Glavno merilo učinkovitosti je bilo število preživelih bolnikov brez ponovitve bolezni.
It must not be given as a bolus injection (all at once). 
Ne sme se uporabljati kot bolus injekcija (vsega naenkrat).
The most common side effects with Mepact (seen in more than 1 patient in 10) are anaemia (low red blood cell counts), loss of appetite, headache, dizziness, tachycardia (rapid heartbeat), hypertension (high blood pressure), hypotension (low blood pressure), dyspnoea (difficulty breathing), tachypnoea (rapid breathing), cough, vomiting, diarrhoea, constipation, abdominal pain (stomach ache), nausea, hyperhidrosis (excessive sweating), myalgia (muscle pain), arthralgia (joint pain), back pain, pain in extremity (the arms and legs), fever, chills, fatigue (tiredness), hypothermia (low body temperature), general pain, malaise (feeling unwell), asthenia (weakness) and chest pain. 
Najpogostejši neželeni učinki zdravila Mepact (opaženi pri več kot 1 bolniku od 10) so anemija (majhno število rdečih krvničk), izguba apetita, glavobol, vrtoglavica, tahikardija (hitro bitje srca), hipertenzija (visok krvni tlak), hipotenzija (nizek krvni tlak), dispneja (oteženo dihanje), tahipneja (hitro dihanje), kašelj, bruhanje, driska, zaprtje, bolečine v trebuhu, slabost, hiperhidroza (pretirano potenje), mialgija (bolečine v mišicah), artralgija (bolečine v sklepih), bolečine v hrbtu, bolečine v okončinah (v rokah in nogah), zvišana telesna temperatura, mrzlica, utrujenost, hipotermija (nizka telesna temperatura), splošna bolečina, občutek neugodja, astenija (šibkost) in bolečina v prsih.
The European Commission granted a marketing authorisation valid throughout the European Union for Mepact on 6 March 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Mepact, veljavno po vsej Evropski uniji, odobrila dne 6. marca 2009.
‘High grade' means that the cancer is of a severe type, and ‘non-metastatic' means that it is at an early stage and has not spread far within the body. 
„Visoka stopnja“ pomeni, da je rak hujše oblike, „nemetastatski“ pa pomeni, da je v zgodnji fazi in da se ni razširil daleč po telesu.
Other information about Mepact: 
Druge informacije o zdravilu Mepact:
After surgery to remove the cancer, all of the patients were given various combinations of anticancer medicines. 
Po kirurški odstranitvi raka so vsi bolniki prejeli različne kombinacije zdravil za zdravljenje raka.
Mepact, used with other anticancer medicines, increased how long patients survived without their disease coming back: 68% of the patients receiving Mepact (231 out of 338) survived without the disease coming back, compared with 61% of the patients who did not receive it (207 out of 340). 
Zdravilo Mepact je v kombinaciji z drugimi zdravili za zdravljenje raka povečalo trajanje preživetja bolnikov brez ponovitve bolezni: 68 % bolnikov, ki so prejeli zdravilo Mepact (231 od 338), je preživelo brez ponovitve bolezni, v primerjavi z 61 % bolnikov, ki ga niso prejeli (207 od 340).
For more information about treatment with Mepact, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Mepact preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Mepact treatment should be started and supervised by a specialised doctor who has experience in diagnosing and treating osteosarcoma. 
Zdravljenje z zdravilom Mepact mora uvesti in nadzorovati specializiran zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem osteosarkoma.
It works by activating macrophages and monocytes (types of white blood cell that form part of the immune system). 
Deluje tako, da aktivira makrofage in monocite (vrsti belih krvničk, ki so del imunskega sistema).
The precise way that mifamurtide works in osteosarcoma is not fully understood, but it is thought to cause the white blood cells to release chemicals that kill the cancerous cells. 
Natančen mehanizem, s katerim mifamurtid deluje na osteosarkom, ni v celoti znan, domneva pa se, da povzroči sprostitev kemičnih snovi iz belih krvničk, ki uničijo rakave celice.
What benefit has Mepact shown during the studies? 
Kakšne koristi je zdravilo Mepact izkazalo med študijami?
The summary of the opinion of the Committee for Orphan Medicinal Products for Mepact is available here. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Mepact je na voljo tukaj.
This document is a summary of the European public assessment report (EPAR) for Mepact. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Mepact.
The dose of Mepact depends on the patient's height and weight. 
Odmerek zdravila Mepact je odvisen od bolnikove telesne višine in mase.
It must not be used at the same time as ciclosporin or other calcineurin inhibitors (medicines that reduce the activity of the immune system), or high doses of non-steroidal anti-inflammatory drugs (NSAIDs; used to treat pain and inflammation). 
Ne sme se uporabljati hkrati s ciklosporinom ali drugimi inhibitorji kalcinevrina (zdravili, ki zmanjšajo delovanje imunskega sistema) ali z visokimi odmerki nesteroidnih protivnetnih zdravil (NSAID, ki se uporabljajo za zdravljenje bolečine in vnetja).
Because the number of patients with osteosarcoma is low, the disease is considered ‘rare', and Mepact was designated an ‘orphan medicine' (a medicine used in rare diseases) on 21 June 2004. 
Ker je bolnikov z osteosarkomom malo, velja bolezen za redko, zato je bilo zdravilo Mepact 21. junija 2004 določeno kot „zdravilo sirota“ (zdravilo, ki se uporablja pri redkih boleznih).
The study compared patients who were given Mepact with those who were not. 
V študiji so primerjali bolnike, ki so prejeli zdravilo Mepact, in tiste, ki zdravila niso prejeli.
Half of the patients were also given Mepact. 
Polovica bolnikov je prejela tudi zdravilo Mepact.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mepact. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Mepact, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Mepact has been studied in one main study involving 678 patients aged between one and 31 years with high-grade non-metastatic osteosarcoma. 
Zdravilo Mepact je bilo raziskano v eni glavni študiji, v kateri je sodelovalo 678 bolnikov, starih od enega do 31 let z nemetastatskim osteosarkomom visoke stopnje.
Mepact should not be used in people who may be hypersensitive (allergic) to mifamurtide or any of the other ingredients. 
Zdravila Mepact ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) mifamurtid ali katero koli drugo sestavino zdravila.
The risk of dying was also reduced by 28% in patients receiving Mepact. 
Prav tako se je pri bolnikih, ki so prejemali zdravilo Mepact, tveganje za smrt zmanjšalo za 28 %.
Mepact is used to treat high-grade non-metastatic osteosarcoma (a type of bone cancer) in patients aged between two and 30 years. 
Zdravilo Mepact se uporablja za zdravljenje nemetastatskega osteosarkoma (vrste kostnega raka) visoke stopnje pri bolnikih, starih od dve do 30 let.
Mepact is used with other anticancer medicines after the cancer has been removed by surgery. 
Zdravilo Mepact se uporablja v kombinaciji z drugimi zdravili za zdravljenje raka po tem, ko je bil rak kirurško odstranjen.
What is the risk associated with Mepact? 
Kakšna tveganja so povezana z zdravilom Mepact?
The active substance in Mepact, mifamurtide, is an immunomodulator. 
Zdravilna učinkovina zdravila Mepact, mifamurtid, je imunomodulator.
The CHMP decided that Mepact's benefits are greater than its risks when used with other anticancer medicines and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Mepact, kadar se uporablja v kombinaciji z drugimi zdravili proti raku, večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
For the full list of all side effects reported with Mepact, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Mepact, glejte navodilo za uporabo.
Why has Mepact been approved? 
Zakaj je bilo zdravilo Mepact odobreno?
Mepact is given as a slow infusion lasting an hour. 
Zdravilo Mepact se daje v obliki počasne, enourne intravenske infuzije.
Mepact is a powder that is made up into a suspension for infusion (drip into a vein). 
Zdravilo Mepact je prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
It contains the active substance mifamurtide. 
Zdravilo vsebuje zdravilno učinkovino mifamurtid.
How has Mepact been studied? 
Kako je bilo zdravilo Mepact raziskano?
What is Mepact? 
Kaj je zdravilo Mepact?
How does Mepact work? 
Kako zdravilo Mepact deluje?
What is Mepact used for? 
Za kaj se zdravilo Mepact uporablja?
The full EPAR for Mepact can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Mepact je na voljo tukaj.
How is Mepact used? 
Kako se zdravilo Mepact uporablja?
4 implants + 1 applicator 
4 implantati + 1 aplikator
Subcutaneous use sachet (PET/LDPE/alu) 
Implantat subkutana uporaba Vrečka (PET/LDPE/Alu)
Studies lasted for six months or one year. 
Študije so trajale od šest mesecev do enega leta.
The correct dose is determined individually for each patient. 
Ustrezen odmerek se določi za vsakega bolnika posebej.
After 26 weeks of treatment, patients had the option to either stop treatment or continue with it for up to a year. 
Po 26 tednih zdravljenja so se lahko bolniki lahko odločili, ali želijo zdravljenje prekiniti ali ga nadaljevati še eno leto.
Tresiba insulin degludec 
Tresiba insulin degludek
The European Commission granted a marketing authorisation valid throughout the European Union for Tresiba on 21 January 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Tresiba, veljavno po vsej Evropski uniji, izdala 21. januarja 2013.
The full EPAR for Tresiba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tresiba je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Tresiba? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Tresiba?
This is a summary of the European public assessment report (EPAR) for Tresiba. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tresiba.
Other information about Tresiba 
Druge informacije o zdravilu Tresiba
It is available as a solution for injection in a cartridge (100 units/ml) and in a pre-filled pen (100 units/ml and 200 units/ml). 
Na voljo je kot raztopina za injiciranje v injekcijskem vložku (100 enot/ml) in napolnjenem injekcijskem peresniku (100 enot/ml in 200 enot/ml).
Tresiba is injected once a day, preferably at the same time every day. 
Zdravilo Tresiba se injicira enkrat na dan, po možnosti vsak dan ob istem času.
The place within the chosen area should be changed with each injection to reduce the risk of lipodystrophy (changes in the distribution of body fat) under the skin that can affect the amount of insulin absorbed. 
Mesto injiciranja na posameznem delu telesa je treba menjati ob vsakem injiciranju, da se zmanjša tveganje za lipodistrofijo (spremembe v porazdelitvi telesnega maščevja) pod kožo, ki lahko vpliva na količino absorbiranega insulina.
For more information about treatment with Tresiba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Tresiba preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Tresiba is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Tresiba je bil pripravljen načrt obvladovanja tveganj.
Tresiba is a replacement insulin that is very similar to the natural insulin with a difference that it is absorbed more slowly in the body and takes longer to reach its target. 
Zdravilo Tresiba je nadomestni insulin, ki je zelo podoben naravnemu insulinu, a se od njega razlikuje po tem, da se v telesu absorbira počasneje, zato traja dlje, da doseže svoj cilj.
The most frequently reported side effect during treatment with Tresiba (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose levels). 
Najpogosteje opaženi neželeni učinek med zdravljenjem z zdravilom Tresiba (ki lahko prizadene več kot eno osebo od 10) je hipoglikemija (nizke ravni glukoze v krvi).
After 26 weeks of treatment with Tresiba, the average reduction in HbA1c was 0.2 percentage points (HbA1c decreased from 8.2% to 8.0%) compared with a reduction of 0.3 percentage points with insulin detemir (HbA1c decreased from 8.0% to 7.7%). 
Po 26 tednih zdravljenja z zdravilom Tresiba se je HbA1c v povprečju znižal za 0,2 odstotne točke (HbA1c se je z 8,2 % znižal na 8,0 %) v primerjavi z znižanjem za 0,3 odstotne točke pri insulinu detemirju (HbA1c se je z 8,0 % znižal na 7,7 %).
What benefit has Tresiba shown during the studies? 
Kakšne koristi je zdravilo Tresiba izkazalo med študijami?